MK-2206 2HCl

Catalog No.S1078

MK-2206 2HCl Chemical Structure

Molecular Weight(MW): 480.39

MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM in cell-free assays, respectively; no inhibitory activities against 250 other protein kinases observed. Phase 2.

Size Price Stock Quantity  
In DMSO USD 220 In stock
USD 110 In stock
USD 170 In stock
USD 370 In stock
USD 570 In stock
Bulk Discount
Bulk Inquiry

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 180 Publications

19 Customer Reviews

  • Inhibition of AKT signaling abolishes MKK4 phosphorylation on Ser78 in injured axons. Cultures of sensory neurons were treated with 5 µM MK-2206 or 5 µM GDC-0068 for 1 hr prior to axotomy. Axonal proteins harvested at indicated time points after axotomy were subjected to immunoblot analysis.

    Cell, 2015, 160(1-2): 161-76 . MK-2206 2HCl purchased from Selleck.

    Cancer Cell 2013 24, 766-76. MK-2206 2HCl purchased from Selleck.

  • The PI3K or AKT inhibition does not restore sensitivity to WZ4002 in PC9 WZR. PC9GR4 or WZR10 cells were treated with WZ4002 alone at the indicated concentrations or in combination with the AKT inhibitor MK-2206 (1 uM). MK-2206 effectively inhibited AKT in both cells.

    Cancer Discov 2012 2, 934-47. MK-2206 2HCl purchased from Selleck.

    Rap1b negatively regulates neutrophil transcellular migration by limiting PI3K-Akt signaling. (A-D) Effect of Akt inhibitor MK2206 (2 uM), Src inhibitor PP2 (10 uM), or vehicle control (DMSO) on WT or Rap1b-/- neutrophil functions. (A) Percentage of neutrophil transendothelial migration in 3D migration model. (B) ECM degradation assessed on Oregon green-labeled gelatin matrix; (left) representative images on (bar, 10 um) and (right) bar graph is percentage of matrix degradation. (C) Percentage of cells forming multiple protrusions. (D) Percentage of neutrophils present at junction of activated bEND.3 in 3D migration assay. Mean ?SD; n = 3 independent experiments. **, P < 0.01; ***, P < 0.001; NS, not significant using unpaired Student's t test).

    J Exp Med 2014 211(9), 1741-58. MK-2206 2HCl purchased from Selleck.

  • VE-cadherin-induced Akt activation mediates YAP phosphorylation and translocation in ECs. HUVECs were starved for 1h and treated with thrombin (1U) for 1h. Total cell lysates were probed with anti-pAkt, Akt or b-actin antibody. The representative blots of three independent experiments are depicted, and the normalized values for p-Akt are shown. HUVECs were cultured and starved as described as in d and incubated for 8h in complete medium with the Akt inhibitor, MK-2206 (1 uM). pAkt, Akt, pYAP and YAP were detected by western blotting using specific antibodies.

    Nat Commun 2015 6:6943. MK-2206 2HCl purchased from Selleck.

    Inhibitors of AKT or ERK overcome SDF-1a-mediated resistance to ibrutinib-triggered PARP and caspase 3 cleavage in CXCR4S338X-expressing BCWM.1 cells. CXCR4S338X-expressing WM cells were treated with ibrutinib (0.5 uM) alone or in the presence of SDF-1a (20 nM) and/or the AKT inhibitors MK-2206 (0.5 uM) and AZD-5363 (0.5 uM); or the MEK inhibitors AS-703026 (0.25 uM), AZD-6244 (0.5 uM) and UO126 (5.0 uM). (a) Immunoblotting results for phosphoAKT (S473) and phospho-ERK (T202/Y204) in CXCR4S338X-expressing BCWM.1 cells pretreated with ibrutinib with and without AKT or ERK inhibitors, then subjected to SDF-1a stimulation for 2 min. The inhibitory effect of AZD-5363 on AKT, which is known to paradoxically hyper-phosphorylate pAKT(S473) was confirmed by inhibition of the phospho-activity for the downstream AKT targets glycogen synthase kinase 3b and pS6. (b) Immunoblotting results for cleaved PARP and cleaved caspase 3 in CXCR4S338X-expressing BCWM.1 cells treated with ibrutinib and/or AKT or ERK inhibitors for 6 h at IC50 doses. GAPDH, glyceraldehyde 3-phosphate dehydrogenase.

    Leukemia 2015 29(1), 169-76. MK-2206 2HCl purchased from Selleck.

  • Induction of apoptosis positively correlates with FOXO3a protein levels and phosphorylation. (a) Treatment of 11 cell lines seeded in 6-well plates with 8 μM MK-2206 or DMSO for 48 hours. Nuclei were harvested for PI staining and FACS analysis and the differences between drug and no drug are displayed as in Figure b. Both conditions were performed in triplo for each cell line. Below the FACS data is a we stern blot of cell lysates from this panel treated with 8 μM MK-2206 or DMSO and harvested at 24 hours. Each cell line name corresponds to the two western lanes below it and the four cell cycle bars above it.

    Cancer Res 2013 73, 2189-98. MK-2206 2HCl purchased from Selleck.

    IC50 values for an Akt inhibitor (MK-2206) and a MEK inhibitor (U0126) in a panel of mouse and human anaplastic (ATC) and follicular (FTC) carcinoma cell lines. On the bottom, a Western blotting showing the effect on the activation of Akt and ERK1/2 of one hour exposure to these inhibitors (MK-2206: 500 nM, U0126: 10 μM).

    Oncotarget 2011 2, 1109-26. MK-2206 2HCl purchased from Selleck.

  • Mean IL-8 concentrations determined by ELISA of the supernatants of HeLa cells infected with wild-type Salmonella. Kinase inhibitors are indicated on the x axis, and the target families of the inhibitors are indicated above each column. CEC, chelerythrine; Pim Inh, Pim-1 inhibitor 2. Inhibitors that significantly affected IL-8 production relative to the control (P < 0.05, Bonferroni post hoc test from one-way ANOVA) are indicated with an asterisk. Relative cell viability is also shown, as determined by reduction of XTT by viable cells. A450, absorbance at 450 nm.

    Sci Signal 2011 4, rs9. MK-2206 2HCl purchased from Selleck.

    Reducing cellular levels of PtdIns5P by overexpression of PIP4Kα inhibits clonogenic growth of U2OS but enhances cell survival in response to H2O2 stimulation. A) U2OS cells (1000) were plated, allowed to attach overnight, and then treated with DMSO (control), PI-103 (0.5 μM), U0126 (5 μM), or SB203580 (5 μM) for 9 d. Cell colonies were stained using crystal violet. Dried plates were scanned. Representative results are shown. B) U2OS cells (1000) were plated, allowed to attach overnight, and then treated with DMSO (control), MK-2206 (1 μM), triciribine (1 μM), KU0063794 (1 μM), or PI-103 (0.5 μM) for 9 d. Cell colonies were stained using crystal violet. Dried plates were scanned. Representative results are shown.

    FASEB J 2013 27, 1644-56. MK-2206 2HCl purchased from Selleck.

  • A. Western blot analysis of pAKT activation in ovarian cancer cell lines treated with exogenous IGF-1. B. Activation of pAKT by IGF-1 in low-grade ovarian cancer cell lines was blocked by the AKT inhibitor MK-2206 in a dose-dependent manner.

    Gynecol Oncol 2011 123, 13-8. MK-2206 2HCl purchased from Selleck.

    Confocal microscopy images of NO formation. DAF 2 DA-loaded washed platelets (1.0109 platelets/mL) were preincubated at 378C with saline (A), and then stimulated for 1min with 0.1 (B), 1.0 (C) or 10 (D) μM AEA. In Panel (E-F-G) washed platelets were preincubated with 1 μM SR1 (E), 1 Mm MK2206 (F) or 20 μM LY294002 (G), and then stimulated for 1min with 1.0 μM AEA. In panel (H) is reported the effect of 5 mg/mL collagen, used as a positive control. All the experiments were carried out in the presence of 100 μM L-arginine. NO formation was visualized by confocal microscropy as detailed in Methods.

     

     

    J Cell Biochem 2011 112, 924–932. MK-2206 2HCl purchased from Selleck.

  • The AEA effect on eNOS phosphorylation. Washed platelets (1.0109 platelets/mL), preincubated at 378C with saline, 1 μM SR1, 1 μM SR2, 20 μM LY294002, 1 μM MK2206, 1.0 μM EGTA, or 30 μM BAPTA/AM, were stimulated for 1 min with 1.0 μM AEA. At the end of incubation suitable aliquots were immunoblotted with anti-p-eNOSser1177 as detailed in Methods.Blots are representative of five independent experiments.

     

     

    J Cell Biochem 2011 112, 924–932. MK-2206 2HCl purchased from Selleck.

    Effect of selected agents on NOx and cGMP formation induced by AEA. Washed platelets (1.0109 platelets/mL), prewarmed at 378C with saline or 1mM SR1, 1 μM SR2, 20 μM URB597 (URB), 1 μM MK2206 (MK) or 20 μM LY294002 (LY), were incubated for 1min with 100 μM L-arginine in the presence of 1.0 μM AEA. NOx (panel A) and cGMP (panel B) content were determined as detailed in Methods. Each bar represents the meanSD of five independent experiments carried out in triplicate. Student,s t-test: P <0.0001 versus none;P <0.0005; P <0.005 versus AEA

     

     

    J Cell Biochem 2011 112, 924–932. MK-2206 2HCl purchased from Selleck.

  • C.U87MG cells were treated with vehicle or 1 μM MK-2206 for 1 hr, and then irradiated with 6 Gy. Total cell lysate was harvested 1 hr after IR and subjected to Western blot analysis with the indicated antibody. Cells without IR treatment were used as a control.

    D. Cells were treated with vehicle (control) or 1 μM MK-2206 for 1 hr, then irradiated with indicated dosage. 4 hr after IR, cells were fed with drug-free medium, and incubated for another 20 hr at 37°C, after which they were trypsinized and seeded for clonogenic survival assay. Colony-forming efficiency was determined 14 d later.
     

     

    Radiat Oncol 2009 4, 43. MK-2206 2HCl purchased from Selleck.

    MK-2206 2HCL inhibited the sorafenib-induced PI3K/mTOR pathway activation and enhanced the cytotoxic effects of sorafenib in resistant cell lines. (A) HUH-7 hepatoma cells treated with sorafenib (5 μM) for 24 h with or without pretreatment with specific kinase inhibitors (MK-2206 2HCL, 15 μM). The expressions of p-AKT and cleaved PARP were revealed by Western blotting. (B) SK-HEP-1 hepatoma cells treated with sorafenib (5 μM) for 24 h with or without pretreatment with specific kinase inhibitors (MK-2206 2HCL, 15 μM). The expressions of p-AKT and cleaved RARP were revealed by Western blotting. (C) HUH-7 hepatoma cells treated with sorafenib (5 μM) with or without the kinase inhibitors for 24 h. The proportions of apoptotic cells were evaluated by annexin V labeling. (D) SK-HEP-1 hepatoma cells treated with sorafenib (5 μM) with or without the kinase inhibitors for 24 h. The proportions of apoptotic cells were evaluated by annexin V labeling. (*P < 0.05, HUH-7, SK-HEP-1 are control groups, R-HUH-7, R-SK-HEP-1 are resistant groups).

    J Surg Res, 2016, 206(2):371-379. MK-2206 2HCl purchased from Selleck.

  • Comparative effects of inhibitors by immunofluorescence microscopy study. Confluent HC11 cells were grown on poly-L-lysine-coated glass coverslips (immunofluorescence) and on plastic plates (biochemical control) and then treated with inhibitors according to the standard procedure. Upper part: the biochemical action of the inhibitors was tested to validate the immunofluorescence results. Cellular proteins were analyzed by SDS-PAGE and the immunoblots were successively probed with anti-ADRP, anti-β-casein, and anti- β-actin antibodies and their respective HRP-conjugated secondary antibodies. Each experimental condition was performed in duplicate. Lower part: cells were fixed, permeabilized and subjected to immunofluorescence microscopy using antiserum against ADRP and TRITC-conjugated secondary antibody (red).

    Biochim Biophys Acta 2012 1823, 987-96. MK-2206 2HCl purchased from Selleck.

    After starved in serum-free medium for 24h, Breast cancer cells incubated with the indicated concentrations of MK-2206 for 3h,followed by 15-minute stimolation of 100ng/ml EGF.

     
     

     

    Dr. Zhang of Tianjin Medical University. MK-2206 2HCl purchased from Selleck.

  •  

    PI3K pathway signaling in GDC-0941 and MK-2206 treated MCF-7 derivatives with PIK3CA or  AKT1 mutations. Cells were grown in medium containing 5% FBS and treated with vehicle or increasing concentrations of GDC-0941 (0 nM, 50 nM, 100 nM, and 400 nM) or MK-2206 (0 nM, 100 nM, 250 nM, 1000 nM). After 24 hours of drug treatment, lysates were prepared and equal amounts of protein were load ed onto SDS-PAGE gels and blotted with the indicated antibodies.

    MK-2206 2HCl purchased from Selleck.

Purity & Quality Control

Choose Selective Akt Inhibitors

Biological Activity

Description MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM in cell-free assays, respectively; no inhibitory activities against 250 other protein kinases observed. Phase 2.
Features The first allosteric small molecule inhibitor of Akt to enter clinical development.
Targets
Akt1 [1]
(Cell-free assay)		 Akt2 [1]
(Cell-free assay)		 Akt3 [1]
(Cell-free assay)
8 nM 12 nM 65 nM
In vitro

MK-2206 is an allosteric inhibitor and is activated by the pleckstrin homology domain. MK-2206 inhibits auto-phosphorylation of both Akt T308 and S473. MK-2206 also prevents Akt-mediated phosphorylation of downstream signaling molecules, including TSC2, PRAS40 and ribosomal S6 proteins. [1] MK-2206 inhibits Ras wild-type (WT) cell lines (A431, HCC827, and NCI-H292) more potently when compared to Ras-mutant cell lines (NCI-H358, NCI-H23, NCI-H1299, and Calu-6). MK-2206 also shows synergistic responses in combination with cytotoxic agents such as erlotinib or lapatinib in lung NCI-H460 or ovarian A2780 tumor cells. [2] MK-2206 or siRNA-mediated Akt inhibition strongly activates autophagy in human glioma cells. However, eukaryotic elongation factor-2 (eEF-2) silencing suppresses MK-2206-induced-autophagy, with a promotion of apoptotic cell death. [3]
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
NCI-H292 MkX3R5l1d3SxeHnjJGF{e2G7 M123VVMh|ryP NWDwSHZNPzJiaB?= MmOwSG1UVw>? M1P0SWlvcGmkaYTpc44hd2ZiY3XscEBxem:uaX\ldoF1cW:w M4n1UVIxPTdzME[5
A431 NYXteopxU2mwYYPlJGF{e2G7 M4XrblUh|ryP MUS1JIg> NYSxOY9vTE2VTx?= NXviflQzW3WycILld5NmeyC2aHWgd4lodmGuaX7nJI9nKEGtdDDhcoQhTXKt MYeyNFU4OTB4OR?=
HepG2 MX\DfZRwfG:6aXOgRZN{[Xl? M{PyRVExKM7:TR?= NVHvOpBoOjRiaB?= MXPEUXNQ MUnT[Y5{cXSrenXzJJJme2m|dHHueEBk\WyuczD0c{B1cGViY4n0c5RwgGmlIHXm[oVkfCCxZjDzc5Ji\mWwaXK= NWn2WmpQOjF{MEW5NlU>
Sk-Hep1 NELT[GNEgXSxdH;4bYMhSXO|YYm= M2jSS|ExKM7:TR?= NH[0TJEzPCCq MofnSG1UVw>? NXfvXmhuW2Wwc3n0bZpmeyC{ZYPpd5RidnRiY3XscJMhfG9idHjlJIN6fG:2b4jpZ{Bm\m[nY4Sgc4Yhe2:{YX\lcolj NFr5NYwzOTJyNUmyOS=>
OCUT1 cells harbored PIK3CA (H1047R+/+) NE\YempIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnCN{DPxE1? MXS1JIQ> NXz0dmNSTE2VTx?= M4XMUmlEPTB;MD6xOEDPxE1? Mn75NlEzQDl{Nke=
K1 cells harbored PIK3CA (E542K+/+) NEDmSJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXOzJO69VQ>? NHPWOZo2KGR? NFzZeYZFVVOR NV;leZpRUUN3ME2wMlUzKM7:TR?= M1y4S|IyOjh7Mk[3
FTC133 cells harbored PTEN (allele deletion and R130+) NX;xSGNXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUCzJO69VQ>? M1\SVlUh\A>? NWTzTo9TTE2VTx?= MmPxTWM2OD1yLkG4JO69VQ>? NEH0fWwzOTJ6OUK2Oy=>
C643 cells harbored HRAS (G13R+/−) NEW4WJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTwN{DPxE1? NV;XOnJDPSCm Ml:xSG1UVw>? MmLSTWM2OD1yLkK3JO69VQ>? NXTQRWVxOjF{OEmyOlc>
Hth7 cells harbored NRAS (Q61R+/−) Ml35S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrHN{DPxE1? MV:1JIQ> MYPEUXNQ M3\XfmlEPTB;ND61JO69VQ>? NGPEcYYzOTJ6OUK2Oy=>
TPC1 cells harbored RET/PTC1 rearrangement NFTGS3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYGzJO69VQ>? M2DaWlUh\A>? MnjYSG1UVw>? NUOwNm9UUUN3ME2wMlU6KM7:TR?= M1;oUVIyOjh7Mk[3
Hth74 M3XV[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWP0ZnJrOyEQvF2= M1PsNlUh\A>? MXzEUXNQ MVvJR|UxRTJwMUmg{txO MYmyNVI5QTJ4Nx?=
KAT18 NGO0[WRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHvb5ZsOyEQvF2= Mn;DOUBl MlTYSG1UVw>? MV\JR|UxRTRwNkKg{txO NV\aZm9xOjF{OEmyOlc>
SW1736 NWXRS4MzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LGU|ExOCEQvF2= NHnkeZQ2KGR? MnXYSG1UVw>? NWrmfIZPUUN3ME20O{42PiEQvF2= Mn71NlEzQDl{Nke=
WRO NFK2TYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TlPVExODBizszN M2rabFUh\A>? NVrtU4FCTE2VTx?= MlHaTWM2OD5zMECwJO69VQ>? NWDHfGlNOjF{OEmyOlc>
TAD2 M{j5XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjyNVAxOCEQvF2= Moi2OUBl Ml7zSG1UVw>? MoG0TWM2OD5zMECwJO69VQ>? M3LuO|IyOjh7Mk[3
LN229 MlfzRZBweHSxc3nzJGF{e2G7 MonDNE42KM7:TR?= NFTBO|U3OCCq NFPZe2JFVVOR NV\HfY1ZSXWpbXXueJMh[XCxcITv[4VvcWNiZX\m[YN1eyCxZjDn[YZqfGmwaXK= MUKyNlA2PzlzNB?=
T98G MUHBdI9xfG:|aYOgRZN{[Xl? NX3IfmJPOC53IN88US=> M4\UbFYxKGh? NX7ReIlJTE2VTx?= M{naR2F2\22nboTzJIFxd3C2b3flcolkKGWoZnXjeJMhd2ZiZ3XmbZRqdmmk MlH6NlIxPTd7MUS=
HC11 NXfrU2V4TnWwY4Tpc44hSXO|YYm= M3\CXFExKM7:TR?= M3HWXVI1KGh? MYnEUXNQ MlTITY5pcWKrdIOg{tIu[2G|ZXnuJIFv\CCDRGLQJJN6dnSqZYPpdy=> NGrZbmwzOjR{Nk[yNS=>
MOLT-4 MWTDfZRwfG:6aXOgRZN{[Xl? NGWze3EyOCEQvF2= NInFVYU1QCCq NXf0UVI2TE2VTx?= NWXPPFNyUUN3ME2xMlfjiIoQvF2= MWeyNlYyPDJ2Mx?=
CEM-R NV:4UlBXS3m2b4TvfIlkKEG|c3H5 NFTKcXAyOCEQvF2= NUPaR4p5PDhiaB?= MnnYSG1UVw>? MWHJR|UxRTNwM,MAje69VQ>? NIiwXmszOjZzNEK0Ny=>
CEM-S MoXVR5l1d3SxeHnjJGF{e2G7 MnfWNVAh|ryP NEDGTIs1QCCq MV;EUXNQ MYXJR|UxRTVwMfMAje69VQ>? MlrHNlI3OTR{NEO=
MOLT-4 NFPDVZRHfW6ldHnvckBCe3OjeR?= NVK5PYJKOTBizszN MYiyOEBp MYrEUXNQ MVPCcI9kc3NiY3XscJMhcW5idHjlJGcxN0dzIIDoZZNmKG:oIITo[UBk\WyuIHP5Z4xm MorFNlI3OTR{NEO=
MOLT-4 MmC3SpVv[3Srb36gRZN{[Xl? MYi05qCK|ryP M{PFdVQhcA>? NIDXPG9FVVOR NGXVWnpKdmO{ZXHz[ZMhfGinIHHtc5VvfCCxZjDjcIVifmWmIFzDN2EwSixiYTD3[YxtNWW|dHHicIl{cGWmIHH1eI9xcGGpeTDtZZJs\XJ? NGO0U5YzOjZzNEK0Ny=>
CEM-R MWPGeY5kfGmxbjDBd5NigQ>? NUPNdXVnPOLCid88US=> MkjJOEBp M1GxWWROW09? M2nMXWlv[3KnYYPld{B1cGViYX3veY51KG:oIHPs[YF3\WRiTFO0RU9DNCCjIIflcIwu\XO2YXLsbZNp\WRiYYX0c5Bp[We7IH3hdotmeg>? MojoNlI3OTR{NEO=
CEM-S M1yzbmZ2dmO2aX;uJGF{e2G7 MUC05qCK|ryP MW[0JIg> M3fLb2ROW09? MUHJcoNz\WG|ZYOgeIhmKGGvb4XueEBw\iClbHXheoVlKEyFNVGvRkwh[SC5ZXzsMYV{fGGkbHnzbIVlKGG3dH;wbIFogSCvYYLr[ZI> MXOyNlYyPDJ2Mx?=
HepG2 cell NWDTZY9[U2mwYYPlJGF{e2G7 M4LqR|IxKM7:TR?= NG\HOlczPCCq NIrpUYhFVVOR NYWxfph3TG:5boLl[5Vt[XSnczD0bIUheGixc4Doc5J6dGG2aX;uJI9nKEGNVB?= MXSyN|c6PzNzOR?=
HepG2 cell NI[zfGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFSzTFg{OCEQvF2= MmfINlQhcA>? MWDEUXNQ MmrsTY5pcWKrdIOgZ4VtdCCpcn;3eIg> NYewNlZDOjN5OUezNVk>
HepG2 cell NHHsZlVCeG:ydH;zbZMhSXO|YYm= MY[yNEDPxE1? MXyyOEBp MnTBSG1UVw>? MYfJcoR2[2W|IHPlcIwh[XCxcITvd4l{ Mlv4NlM4QTd|MUm=
GEO M1zlemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTLXWk{PTByIH7N NFPGXVE4OiCq MWDEUXNQ M3vqVmlvcGmkaYTzJINmdGxiZ4Lve5Rp Ml3yNlQ2QDF{M{G=
CNE-1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{G4d|ExKM7:TR?= MWe5OkBp MlXZSG1UVw>? MYfJR|UxRTJwOU[g{txO MXWyOVM{Pjl{NR?=
CNE-2 Mmj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1OxfVExKM7:TR?= MoPjPVYhcA>? NHHVXFZFVVOR MlTWTWM2OD12LkWzJO69VQ>? NYDyXoplOjV|M{[5NlU>
HONE-1 MkXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4Tj[VExKM7:TR?= MXe5OkBp MYLEUXNQ NHy0e2FKSzVyPUOuN|ch|ryP MoHLNlU{OzZ7MkW=
SUNE-1 M{f5RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fWRVExKM7:TR?= MXe5OkBp MYTEUXNQ M3nKV2lEPTB;MD61NkDPxE1? NFvGeWQzPTN|NkmyOS=>
CNE-2 MUPGeY5kfGmxbjDBd5NigQ>? Ml\QNVAh|ryP MofZOFghcA>? Mn;vSG1UVw>? NHLWcFNKdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0JIF1KEdz NWT3PJdUOjV|M{[5NlU>
HONE-1 MXPGeY5kfGmxbjDBd5NigQ>? NXv2cJVwOTBizszN MUe0PEBp MWLEUXNQ NXXLRolvUW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeEBifCCJMR?= NV[4WGRXOjV|M{[5NlU>
NEC8 NED3NlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTBwMEm2OVEh|ryP M3jk[HNCVkeHUh?=
P12-ICHIKAWA MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnVUGFKSzVyPUCuNVE3OiEQvF2= NIHrbWJUSU6JRWK=
MDA-MB-175-VII MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPRWldoUUN3ME2wMlE{PzN6IN88US=> NVi1b2ZxW0GQR1XS
AsPC-1 M3rvWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPyTWM2OD1yLkKyNVIzKM7:TR?= NV3OcZg5W0GQR1XS
T47D NHnvR3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\WZWlEPTB;MD6yPFI2KM7:TR?= MUPTRW5ITVJ?
HH NXT0WG1HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4X5OWlEPTB;MD6zNFI5OyEQvF2= Mn;ZV2FPT0WU
MOLT-16 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjITWM2OD1yLkOwN|Ih|ryP NIDGcm1USU6JRWK=
ES5 MoLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTBwM{S0OVUh|ryP NXzUOoNoW0GQR1XS
RS4-11 NEGze|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjZW4d{UUN3ME2wMlM1PjFizszN M2rHfnNCVkeHUh?=
KARPAS-45 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXu4VIxpUUN3ME2wMlM4OzJzIN88US=> M{m1b3NCVkeHUh?=
NCI-H720 NXXXXJdWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYr3Vm1DUUN3ME2wMlM4Pjd7IN88US=> NHTMcJlUSU6JRWK=
H9 Mo\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\KcVFKSzVyPUCuN|g5QDNizszN M{DOZ3NCVkeHUh?=
EFM-19 NVrGVFJ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{j4[2lEPTB;MD60OFAyKM7:TR?= MYTTRW5ITVJ?
SBC-1 M3jxVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTBwNESwN|Uh|ryP NEfKWoZUSU6JRWK=
A4-Fuk NWHFNnNST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnMUHllUUN3ME2wMlQ3QDZ6IN88US=> MWnTRW5ITVJ?
NCI-H1563 NUO3fGJDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFj6T|BKSzVyPUCuOFgyQDlizszN Moe0V2FPT0WU
HCC1419 M3XESWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLheWsxUUN3ME2wMlQ5QDl{IN88US=> NEL2[4VUSU6JRWK=
H-EMC-SS MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGmzNXRKSzVyPUCuOFk6OzlizszN NHPtcWhUSU6JRWK=
BHT-101 NGrq[XhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzFTWM2OD1yLkWyPVYyKM7:TR?= MUjTRW5ITVJ?
IGROV-1 M{DMcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1e0cmlEPTB;MD61OVI1QSEQvF2= NF;KRpNUSU6JRWK=
HGC-27 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HXUGlEPTB;MD61Olc5OyEQvF2= M1;FO3NCVkeHUh?=
MDA-MB-361 NVOwc|Y1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3jbmlKSzVyPUCuOVc4PjFizszN MUjTRW5ITVJ?
KE-37 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jvRWlEPTB;MD61PFI3KM7:TR?= NWfZZ2pkW0GQR1XS
HCC70 MnixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\1OmlEPTB;MD61PVgzPyEQvF2= NX\GZW5uW0GQR1XS
LNCaP-Clone-FGC NUfGZ2p4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknWTWM2OD1yLk[xNFQ5KM7:TR?= M4LBU3NCVkeHUh?=
HAL-01 NH64e3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PJUGlEPTB;MD62NlE{KM7:TR?= NWrJVHlTW0GQR1XS
HT M{G1cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPHTWM2OD1yLk[zNlM6KM7:TR?= MWLTRW5ITVJ?
MDA-MB-415 NV;j[VNCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTBwNkO2NlYh|ryP Mm\5V2FPT0WU
NOS-1 M4D5VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvpTWM2OD1yLk[zO|I{KM7:TR?= NIm1RVVUSU6JRWK=
DU-145 M1\uSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{f3U2lEPTB;MD62OFc1PSEQvF2= NHLOXYZUSU6JRWK=
OCUB-M NFzpT29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfaTWM2OD1yLkewPVY3KM7:TR?= MXTTRW5ITVJ?
VA-ES-BJ NXW2b3F2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTBwN{OwNlUh|ryP MnrPV2FPT0WU
J-RT3-T3-5 MmSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjOUo5KSzVyPUCuO|Q1ODNizszN MVPTRW5ITVJ?
MOLT-4 NXGycYlHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTBwOEC1PFIh|ryP M3jUXnNCVkeHUh?=
NB7 M2PDRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorQTWM2OD1yLkiyOFEyKM7:TR?= M2rMO3NCVkeHUh?=
L-363 NWDx[FFrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTBwOEO0OFIh|ryP Mn;MV2FPT0WU
NKM-1 NXrxOXczT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTBwOE[yOVMh|ryP MV3TRW5ITVJ?
HOP-92 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rXNWlEPTB;MD64O|IzOyEQvF2= MUjTRW5ITVJ?
OAW-42 NX\KfIFYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\uR4NJUUN3ME2wMlg5PzJizszN NIi4OnlUSU6JRWK=
HuO9 M{DBNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPETWM2OD1yLkmyO|UyKM7:TR?= NYfSV|ZSW0GQR1XS
MFE-280 MmrSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrzOI9KSzVyPUCuPVY1PjVizszN NHLFUWNUSU6JRWK=
EM-2 NFHn[nRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTBSXBKSzVyPUCuPVc6OzlizszN MYDTRW5ITVJ?
NCI-H520 NXrOPWsyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXOOHJKSzVyPUCuPVg2QTJizszN MUTTRW5ITVJ?
LB2241-RCC M2PJVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTBwOUm3N|Qh|ryP NVjJeIttW0GQR1XS
SK-NEP-1 MnfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LV[2lEPTB;MT6xOFQ5PSEQvF2= NIG1Z4dUSU6JRWK=
LXF-289 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjlTWM2OD1zLkG3NVU3KM7:TR?= MYLTRW5ITVJ?
EPLC-272H MlHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PiSWlEPTB;MT6xO|I2PiEQvF2= NVK5SoV5W0GQR1XS
COLO-684 NEDtOWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTFwMkO3NlUh|ryP MUXTRW5ITVJ?
ES1 M1PWW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NED5PGlKSzVyPUGuNlQxPjVizszN NEfNO4JUSU6JRWK=
DOHH-2 M1TJcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;1TWM2OD1zLkK4NlA{KM7:TR?= M4q3S3NCVkeHUh?=
CTB-1 M1vEOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPSSoFKSzVyPUGuNlg6QSEQvF2= M3nZ[nNCVkeHUh?=
G-401 NE\PXpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU[ydoZpUUN3ME2xMlI6Pzl3IN88US=> M4CyenNCVkeHUh?=
LoVo Mn;zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTFwM{K1N|Qh|ryP NYOy[oZtW0GQR1XS
Ramos-2G6-4C10 NY\MR45MT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\sWWRNUUN3ME2xMlM{PzBzIN88US=> MlTVV2FPT0WU
MFM-223 MojnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnX4TWM2OD1zLkO0OFYyKM7:TR?= MnnhV2FPT0WU
PA-1 M{jlOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\CTWM2OD1zLkO1NlY2KM7:TR?= M4rIOXNCVkeHUh?=
697 MnXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4q5RmlEPTB;MT6zO|YyPiEQvF2= NX7WdppwW0GQR1XS
QIMR-WIL NW\vXYprT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk[2TWM2OD1zLkS5NVE3KM7:TR?= Mm\nV2FPT0WU
HOS NH3pcYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTFwNEm1OVgh|ryP Mn7aV2FPT0WU
DMS-273 NXLYR|E6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTFwNUG5OVkh|ryP MV7TRW5ITVJ?
ME-180 Ml;oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mne0TWM2OD1zLkW2PFkyKM7:TR?= NIL1fJdUSU6JRWK=
HCC2218 NIr5Vo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTQZlBFUUN3ME2xMlY5OjJ3IN88US=> MknQV2FPT0WU
CAL-54 M1zWV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHpfVF7UUN3ME2xMlcyOjR{IN88US=> NWrod3NUW0GQR1XS
OMC-1 NU\vV5JoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV[zO4c4UUN3ME2xMlc1Pjd5IN88US=> NICyc4VUSU6JRWK=
COR-L105 NH3OWnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rWSGlEPTB;MT63PVc{PyEQvF2= MnfYV2FPT0WU
BV-173 NYnBWYk6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIn6PWpKSzVyPUGuPFExPzRizszN NVLoSIU3W0GQR1XS
RKO M4HvV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWWyRVZSUUN3ME2xMlg4OTBzIN88US=> MWPTRW5ITVJ?
SNU-387 MkP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHRN2VLUUN3ME2xMlg5PDB4IN88US=> NFy3ZpJUSU6JRWK=
SW1088 MmH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTFwOUS2NFYh|ryP MYfTRW5ITVJ?
Hs-578-T Mmm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTn[XN3UUN3ME2yMlEyPDN|IN88US=> NVjsN2RmW0GQR1XS
OC-314 M1v0W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7zVGhlUUN3ME2yMlE2ODh4IN88US=> MVjTRW5ITVJ?
RMG-I NYXldVZST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPYTWM2OD1{LkG2N|k5KM7:TR?= NIDtZ5RUSU6JRWK=
NCI-H1395 NV3meFlFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zhWGlEPTB;Mj6xPFA6OSEQvF2= MYDTRW5ITVJ?
GAMG M3XUbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTJwMkO4OFUh|ryP MU\TRW5ITVJ?
LB1047-RCC MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Moj5TWM2OD1{LkK0N|E4KM7:TR?= MmfRV2FPT0WU
MN-60 NEKwWJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfxTWM2OD1{LkK5PVI{KM7:TR?= MVLTRW5ITVJ?
OAW-28 NHnCOG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTJwMkm5OVEh|ryP MYLTRW5ITVJ?
NCI-H2228 M3n3Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkCzTWM2OD1{LkOxOVUzKM7:TR?= NEjBXVFUSU6JRWK=
ABC-1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfLNYszUUN3ME2yMlM{OjV|IN88US=> M33NSnNCVkeHUh?=
LS-513 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTJwM{O0PFQh|ryP NXrhfnZ6W0GQR1XS
KS-1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPPSlBKSzVyPUKuN|gyQTFizszN M4fTUHNCVkeHUh?=
NB69 NWW5TXRVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfV[5NKSzVyPUKuN|g6QDNizszN MmDOV2FPT0WU
VM-CUB-1 MorLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYrUXXdvUUN3ME2yMlM6ODh|IN88US=> M1G0XnNCVkeHUh?=
D-423MG NXrOe2V2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTY[HNKSzVyPUKuOFExPDRizszN M3HOTnNCVkeHUh?=
EW-18 MkLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDqfZBTUUN3ME2yMlQyQTN7IN88US=> M{LRNHNCVkeHUh?=
YH-13 NEjvWFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M171WWlEPTB;Mj60OlE2OyEQvF2= M4rB[3NCVkeHUh?=
T-24 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTJwNEe4PFEh|ryP NYTJRYprW0GQR1XS
ES8 M17LWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzFTWM2OD1{LkS5Nlg4KM7:TR?= M4r3T3NCVkeHUh?=
ES3 NEK4UHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjxZnNZUUN3ME2yMlQ6PzV7IN88US=> MlvZV2FPT0WU
RXF393 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nWUWlEPTB;Mj62NFQ5PyEQvF2= MlHMV2FPT0WU
RPMI-8226 Mom0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\HboNKSzVyPUKuOlI6PTNizszN MVHTRW5ITVJ?
AGS M4jHdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1[1V2lEPTB;Mj63NlE{PyEQvF2= NXTPRYNSW0GQR1XS
HCC1395 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYD3WmdPUUN3ME2yMlc2OTh5IN88US=> NX;aU2JqW0GQR1XS
MV-4-11 M1PPWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nKUmlEPTB;Mj63OVI3PiEQvF2= NXjESIVtW0GQR1XS
A204 Mlv3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXKRo1KSzVyPUKuPFM5PzJizszN MVLTRW5ITVJ?
MCF7 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\ZTJVuUUN3ME2yMlg3OTF5IN88US=> NEntb|BUSU6JRWK=
SNU-423 NETXeGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XJd2lEPTB;Mj64PVI1OiEQvF2= NF;nUIFUSU6JRWK=
NCI-H1048 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUj1UpV1UUN3ME2yMlk3QDZ3IN88US=> NXnIT2JLW0GQR1XS
GR-ST MmjsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PBTGlEPTB;Mz6wOFYyOSEQvF2= MnjwV2FPT0WU
EoL-1- M4XEOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnLTWM2OD1|LkC3NFU5KM7:TR?= MkjMV2FPT0WU
HuH-7 NVLtT|U6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVyySJFsUUN3ME2zMlA6PDZ2IN88US=> NVyyOoppW0GQR1XS
OS-RC-2 NX\L[Jl5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfVTWM2OD1|LkGxNVkh|ryP MVHTRW5ITVJ?
EW-3 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLMXGxrUUN3ME2zMlE6PTJ7IN88US=> M2P0VnNCVkeHUh?=
NCI-H747 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DX[GlEPTB;Mz6yNFY6PCEQvF2= NXTnO4E6W0GQR1XS
EW-16 MorXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDJTWM2OD1|LkKxPFc6KM7:TR?= NFvRfFlUSU6JRWK=
DOK MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljKTWM2OD1|LkKyPFU6KM7:TR?= MlvpV2FPT0WU
HCC2157 MkX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVKzVJV7UUN3ME2zMlM5OTd7IN88US=> MnXKV2FPT0WU
OVCAR-3 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTNwNEC3PFYh|ryP MY\TRW5ITVJ?
NCI-H1623 NYfuW44yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjER|c6UUN3ME2zMlQyOjJ2IN88US=> MWjTRW5ITVJ?
H4 NFrLVItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTNwNEW2NlYh|ryP NIe5Xm9USU6JRWK=
SW1710 M1HGWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rUO2lEPTB;Mz60OlY4QCEQvF2= MWTTRW5ITVJ?
RT-112 M4Hkemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXFVFV3UUN3ME2zMlUzOzh6IN88US=> MoLnV2FPT0WU
DMS-114 M3Pncmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vYcmlEPTB;Mz62NlI4QCEQvF2= MXzTRW5ITVJ?
AN3-CA NG\iPFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfOWGZKSzVyPUOuOlI1PTZizszN NVznbG9MW0GQR1XS
KNS-62 M3m0NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nPfWlEPTB;Mz62N|M{QCEQvF2= MnrWV2FPT0WU
SJRH30 MlLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTNwNkmxNlIh|ryP M3e4N3NCVkeHUh?=
G-402 M2DVTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmL5TWM2OD1|LkewO|EyKM7:TR?= NGqyToxUSU6JRWK=
MHH-PREB-1 NHnNPZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;iVnBKSzVyPUOuO|IxOzhizszN NGLYVXRUSU6JRWK=
P30-OHK MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrW[|BKSzVyPUOuPFA6PzZizszN M1THWXNCVkeHUh?=
RVH-421 NH7XPG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjmOopCUUN3ME2zMlgyPzh6IN88US=> NIjidHpUSU6JRWK=
LU-134-A NGLPR4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTNwOEi0Nlgh|ryP Mnf5V2FPT0WU
ECC10 MlTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTNwOUO2NlIh|ryP Mkn3V2FPT0WU
TGW MlvVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXLN3ZKSzVyPUSuNFI{ODVizszN NHvDUW1USU6JRWK=
MLMA MnH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF36WFhKSzVyPUSuNFI6PjZizszN MXTTRW5ITVJ?
SCC-25 NGX5fGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;JUmlEPTB;ND6wOlU3PiEQvF2= MUHTRW5ITVJ?
TYK-nu M3HVc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUntVYNtUUN3ME20MlA6PTN2IN88US=> NF36S|hUSU6JRWK=
LAMA-84 NHXrOYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXq0cJdNUUN3ME20MlE1OTlzIN88US=> NFTPco5USU6JRWK=
Calu-3 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XtNmlEPTB;ND6yOFQyPiEQvF2= M1Tz[HNCVkeHUh?=
NCI-H460 NYj0VJV3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTRwMk[0OFMh|ryP NFTvdXpUSU6JRWK=
EGI-1 M1rNdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TIOWlEPTB;ND6zO|c4QCEQvF2= MnHUV2FPT0WU
NCI-H292 NEnKeVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTRwM{ixOFYh|ryP NWHuUFd{W0GQR1XS
HCE-T NXO3UGxST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjBU3h2UUN3ME20MlQyPTd7IN88US=> MV;TRW5ITVJ?
EW-11 MkSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH71botKSzVyPUSuOFE5OzhizszN MV\TRW5ITVJ?
ATN-1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHjTWM2OD12LkS0N|A1KM7:TR?= M4LmcnNCVkeHUh?=
NB5 NFvZW|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXTUJRKSzVyPUSuOVM3QTdizszN MW\TRW5ITVJ?
KLE M1PJeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTRwN{CxPVgh|ryP MX7TRW5ITVJ?
CAL-39 NHG5e|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3i5d2lEPTB;ND63NlE1PiEQvF2= Mn7ZV2FPT0WU
TI-73 NIHxSWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\Pc2lEPTB;ND64NFYxQSEQvF2= MVHTRW5ITVJ?
HO-1-N-1 NWTp[Wl{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{L4SWlEPTB;ND65OFIh|ryP NFnSc5dUSU6JRWK=
786-0 M17NW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nndWlEPTB;ND65OFY4OyEQvF2= NFrhfZVUSU6JRWK=
SK-N-DZ MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnJXpBKSzVyPUSuPVYyPDJizszN M{f3NnNCVkeHUh?=
NCI-H446 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnjZWZEUUN3ME21MlIxODB7IN88US=> NGO3VmdUSU6JRWK=
ETK-1 M3T2Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HZT2lEPTB;NT6yNVE3PSEQvF2= M37VSnNCVkeHUh?=
BT-20 NFfoU3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;tNoZKSzVyPUWuNlE{PTNizszN NYLqXWRNW0GQR1XS
MEL-HO MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;pXWlEPTB;NT6zO|M{PiEQvF2= NFTmUpBUSU6JRWK=
CAL-27 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofUTWM2OD13LkS2N|M6KM7:TR?= MVrTRW5ITVJ?
SW872 M3K2S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7nTZNsUUN3ME21MlU6PDJ6IN88US=> MnLoV2FPT0WU
RPMI-2650 NYnxWGdWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYW4UWdiUUN3ME21MlY3OTl7IN88US=> NXvRVWVKW0GQR1XS
PFSK-1 M4jwS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrENHVxUUN3ME21MlczPzN{IN88US=> MXfTRW5ITVJ?
SF295 MonES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fZSGlEPTB;NT64NFY{OyEQvF2= M{PRbXNCVkeHUh?=
Becker M3fue2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLmUI53UUN3ME21Mlg3PDd{IN88US=> MofOV2FPT0WU
Saos-2 NX\he4hjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTVwOE[1N{DPxE1? MWHTRW5ITVJ?
SK-OV-3 MnLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVP6TmpYUUN3ME21Mlk6QDF4IN88US=> M1;0UnNCVkeHUh?=
VMRC-RCZ NXHlVJRJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7IeZZLUUN3ME22MlA5Pzd|IN88US=> NUDxdpVtW0GQR1XS
EW-22 NYnJNoZqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnmyTWM2OD14LkG5OlQ6KM7:TR?= MX3TRW5ITVJ?
BT-474 NGPMT5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInHcY1KSzVyPU[uNlM{KM7:TR?= NYKzOY1nW0GQR1XS
BFTC-909 MkDIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;zOJZKSzVyPU[uN|A{PDVizszN MmLFV2FPT0WU
NB12 M1fDUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnGTWM2OD14LkO5NFcyKM7:TR?= M3;3ZXNCVkeHUh?=
D-263MG MkL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVuxOHRNUUN3ME22MlQ2OTZ7IN88US=> MnLEV2FPT0WU
SNB75 NFzONGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1W2UGlEPTB;Nj62NFE1OyEQvF2= Mn\BV2FPT0WU
A704 NWnRSWt2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIOzb|VKSzVyPU[uOlMxPiEQvF2= M3mzdnNCVkeHUh?=
NCI-H1693 NVXJUZE3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vXcGlEPTB;Nj62N|YxPCEQvF2= NXT3PJpjW0GQR1XS
LN-405 MlfuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LWXWlEPTB;Nj63PVY4OiEQvF2= MkPIV2FPT0WU
CHL-1 NVTZRXl1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzhNGJKSzVyPU[uPFAxPzlizszN M2\i[HNCVkeHUh?=
A498 NFnZeWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2j6[GlEPTB;Nj64NVk3OSEQvF2= M4jJeHNCVkeHUh?=
TE-12 NUHGV3ZpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTZwOEO4NVch|ryP NVXXZ|dZW0GQR1XS
TE-6 NYmxSWx5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLmTWM2OD14LkmzNFM5KM7:TR?= NWPnZ|lJW0GQR1XS
AU565 MkCyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\XW2twUUN3ME22Mlk3QTV5IN88US=> M2ixXnNCVkeHUh?=
RD MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTZwOUiyPFQh|ryP NHzKcYZUSU6JRWK=
SW1463 NH\DRYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1n6ZWlEPTB;Nz6xNVE3QCEQvF2= NXPX[I5qW0GQR1XS
LU-99A MnvZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTEXm5KSzVyPUeuNVQ{OjJizszN NX\ae3ZPW0GQR1XS
NCI-H28 NI\hZphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\mWoJKSzVyPUeuNlkzPCEQvF2= MkPiV2FPT0WU
MC-IXC NITWb|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\yZW1KSzVyPUeuOFg2PzZizszN MonTV2FPT0WU
GP5d MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjadmlKSzVyPUeuOFg4PjRizszN MkLkV2FPT0WU
GB-1 NVPG[XdXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTdwNUS4NFQh|ryP NIDRR4JUSU6JRWK=
CAL-33 NGnyOoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fJTWlEPTB;Nz62OlI{OyEQvF2= MnXkV2FPT0WU
MSTO-211H NYKxPYN3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTdwNkezN|Yh|ryP Mnm0V2FPT0WU
TE-5 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13kb2lEPTB;Nz63PVM{PCEQvF2= NXrvR4E{W0GQR1XS
D-566MG Mn:xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1y2RWlEPTB;OD6wOFQzQSEQvF2= NVr2UWpbW0GQR1XS
JVM-3 NWe1UpM2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3n[YZKSzVyPUiuNVUzPjhizszN NWToeINCW0GQR1XS
T98G MoXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoL2TWM2OD16LkG4NFY4KM7:TR?= MYrTRW5ITVJ?
HCC1954 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRThwNEWxNFQh|ryP NUiwbWdkW0GQR1XS
SF126 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrxU|JKSzVyPUiuOFU6OzZizszN MUPTRW5ITVJ?
LB996-RCC NWi3UIJuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\mNoFKSzVyPUiuOVMzPTdizszN MVPTRW5ITVJ?
SKG-IIIa MlPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTIW4k2UUN3ME24MlY{ODZ7IN88US=> NIDWPXpUSU6JRWK=
NCI-SNU-1 Mlv6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRThwNkS2OFMh|ryP MXfTRW5ITVJ?
LB771-HNC NWHa[otIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYmybWtDUUN3ME24MlY1Pjl4IN88US=> MmLEV2FPT0WU
SCC-4 NXix[JFwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzTXZVNUUN3ME24MlY5OjF7IN88US=> MWDTRW5ITVJ?
CAMA-1 MlLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mle0TWM2OD16Lke3NVQ3KM7:TR?= M2PNSnNCVkeHUh?=
D-502MG NWr3fJE2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHr6NYZKSzVyPUiuO|g3OjlizszN MlHvV2FPT0WU
ESS-1 NV\LSppDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPnTWM2OD16Lki4O|A1KM7:TR?= MWfTRW5ITVJ?
HEC-1 NFy2dnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPKS5o1UUN3ME24Mlg6QDZ4IN88US=> NITqWo1USU6JRWK=
NB10 NYDoTWJtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjGRWdKSzVyPUmuNFIzOjRizszN M37TcXNCVkeHUh?=
8505C MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\RPJpKSzVyPUmuNFQzOzJizszN MmjrV2FPT0WU
EFO-27 NFXk[5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1r0[2lEPTB;OT6xOlQyOiEQvF2= Mn\jV2FPT0WU
HN NIrzPI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDYTWM2OD17LkG2OlI5KM7:TR?= MmWxV2FPT0WU
DSH1 MmrLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULGPIpsUUN3ME25MlIxQDdizszN MkWyV2FPT0WU
NBsusSR M1TLUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37EfWlEPTB;OT6yO|QxOiEQvF2= NWXEbIFpW0GQR1XS
LS-123 NUK2S3Y3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTlwM{G3OlEh|ryP MUnTRW5ITVJ?
SHP-77 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2G0SmlEPTB;OT6zPVk{PSEQvF2= NUGxZnpVW0GQR1XS
ACN NVrYZWV2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fLWmlEPTB;OT61N|I4PyEQvF2= MVXTRW5ITVJ?
U251 NW\jOJNLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PhTmlEPTB;OT62OVU1PCEQvF2= MoXtV2FPT0WU
A431 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTlwOECyN|gh|ryP M37o[XNCVkeHUh?=
5637 MlW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnj1TWM2OD17Lki0PVg1KM7:TR?= MYjTRW5ITVJ?
MDA-MB-157 MmrGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TVVWlEPTB;OT65Nlg4QCEQvF2= NHzvcG9USU6JRWK=
A101D NE\N[mNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTlwOUm5O|Qh|ryP MnzaV2FPT0WU
YKG-1 M3KzVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvPO4RKSzVyPUGwMlIxODZizszN M4XsZXNCVkeHUh?=
LAN-6 M2mwXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXnZ[nFkUUN3ME2xNE4zOTZ2IN88US=> MUDTRW5ITVJ?
OVCAR-5 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTFyLkK0N|Mh|ryP M2fRe3NCVkeHUh?=
A549 M4m3SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELre5NKSzVyPUGwMlM6PzNizszN MVTTRW5ITVJ?
no-11 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2W5V2lEPTB;MUCuOFM2OyEQvF2= MnriV2FPT0WU
SF539 MlLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkH4TWM2OD1zMD65NFQyKM7:TR?= NEfNR3RUSU6JRWK=
A388 Ml\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHy0VlFKSzVyPUGxMlM5QTdizszN NVXKbpRoW0GQR1XS
DEL NHj3[FdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTFzLkSyOEDPxE1? NELaZlVUSU6JRWK=
SW954 MnfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTaWI1JUUN3ME2xNU41PjZ6IN88US=> NHXEeYpUSU6JRWK=
TK10 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEj6SmpKSzVyPUGxMlUzPzFizszN M4LnbHNCVkeHUh?=
SW756 NH62XlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGT1Z3BKSzVyPUGxMlUzQTRizszN NFPFdGFUSU6JRWK=
PC-3 NFz6N5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYO1c5dTUUN3ME2xNU42PzZ2IN88US=> NU\Nd2gxW0GQR1XS
ONS-76 NF;UOlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXv4WVRGUUN3ME2xNU43OzZizszN MX\TRW5ITVJ?
A427 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;tTGlEPTB;MUGuO|A6OyEQvF2= MmnFV2FPT0WU
MEG-01 MkXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHuTWM2OD1zMT63OVA6KM7:TR?= MVPTRW5ITVJ?
BB30-HNC M3rh[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfWTWM2OD1zMT63PVgzKM7:TR?= M1\RWHNCVkeHUh?=
NCI-H1299 M3iwPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXrCcWRMUUN3ME2xNU45ODl|IN88US=> MX3TRW5ITVJ?
GCT NXHMPXA3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzrTWM2OD1zMT64NlI5KM7:TR?= MUPTRW5ITVJ?
D-247MG NF7xPWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTFzLkm2OlMh|ryP Ml64V2FPT0WU
CFPAC-1 M{T1SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnnOWVKSzVyPUGxMlk4QDJizszN MUfTRW5ITVJ?
EKVX NHPHWGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjONHBKSzVyPUGyMlA{OTNizszN M13MSHNCVkeHUh?=
CAL-51 NFXXXmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjGTWM2OD1zMj6wO|E3KM7:TR?= MULTRW5ITVJ?
BB49-HNC NGfBfHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2K4TWlEPTB;MUKuNVE4PyEQvF2= MXnTRW5ITVJ?
RPMI-7951 Mo\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorkTWM2OD1zMj6xPFU1KM7:TR?= MkLYV2FPT0WU
RH-1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jtVmlEPTB;MUKuNlE5PCEQvF2= M{W5VnNCVkeHUh?=
BCPAP MmXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjpZnhkUUN3ME2xNk41PzR7IN88US=> MmDHV2FPT0WU
GCIY MlvJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjSR5IxUUN3ME2xNk42OjB7IN88US=> M2PnVXNCVkeHUh?=
KNS-81-FD MnXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml31TWM2OD1zMj61PFY6KM7:TR?= NETrNXJUSU6JRWK=
KYSE-140 MkPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEficXlKSzVyPUGyMlg2QTVizszN MWPTRW5ITVJ?
Ca-Ski NXv4SGhIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoOwTWM2OD1zMj65NFQyKM7:TR?= M2\hcnNCVkeHUh?=
TGBC1TKB NXrue3ZvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7LTWM2OD1zMj65NVE2KM7:TR?= MWnTRW5ITVJ?
HCC1187 NYmzXlZLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvpVIFKSzVyPUGzMlE6OTJizszN M1vEZnNCVkeHUh?=
SJSA-1 MmrSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnXTWM2OD1zMz6yN|I4KM7:TR?= MlPIV2FPT0WU
CTV-1 NWTMNldST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHGTWM2OD1zMz6zOFUh|ryP NUHucYhpW0GQR1XS
WM-115 NFG0S45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUCwZW1KUUN3ME2xN{43PDh|IN88US=> M12zbnNCVkeHUh?=
CHP-212 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfOOG1KSzVyPUGzMlk4OzlizszN MVLTRW5ITVJ?
SCC-15 MnrOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPEOXNKSzVyPUGzMlk4PzVizszN M3Lu[XNCVkeHUh?=
BPH-1 NIHYfIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTF2LkG2OlQh|ryP NXLKNIpRW0GQR1XS
SW780 MkfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\0WHZnUUN3ME2xOE42ODJ3IN88US=> NXTI[2FPW0GQR1XS
NCI-H2291 M1nZPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm[3TWM2OD1zND61PFc5KM7:TR?= MUDTRW5ITVJ?
JEG-3 NU\3fGxOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjUTWM2OD1zND62N|I3KM7:TR?= NXX4cI1iW0GQR1XS
CAL-120 NWHD[pZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fYWWlEPTB;MUSuO|AzPyEQvF2= NIDCNplUSU6JRWK=
NCI-H23 Mnv6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjDO5ZKSzVyPUG0Mlc6QTdizszN NWXqVWU2W0GQR1XS
MS-1 MkOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrMdIo4UUN3ME2xOE46PjFzIN88US=> NHHkbmtUSU6JRWK=
PC-14 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljwTWM2OD1zND65OlU1KM7:TR?= MYTTRW5ITVJ?
D-283MED MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\YTWM2OD1zNT6wNVEyKM7:TR?= NWjrSnlEW0GQR1XS
OE19 M1\NUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfQW21KSzVyPUG1MlE2PDFizszN M1TBcHNCVkeHUh?=
CAS-1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrMb2xWUUN3ME2xOU41OTh2IN88US=> NYLCS4l7W0GQR1XS
NCI-H727 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnjRmlwUUN3ME2xOU41OjJzIN88US=> M4DYXHNCVkeHUh?=
SiHa MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17oTGlEPTB;MUWuO|U6PCEQvF2= MkjZV2FPT0WU
BFTC-905 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MorwTWM2OD1zNT63Olk1KM7:TR?= M1nVfnNCVkeHUh?=
MDA-MB-453 MnPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M16w[GlEPTB;MU[uNVY1OiEQvF2= NHvyWIVUSU6JRWK=
HuP-T3 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX63bGdqUUN3ME2xOk43Ozd|IN88US=> NIrnVFRUSU6JRWK=
SK-LU-1 MnnRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoqzTWM2OD1zNj62PVU3KM7:TR?= M3r3fnNCVkeHUh?=
Detroit562 NXi3[mMxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzMTWM2OD1zNj63N|E5KM7:TR?= NH\DcItUSU6JRWK=
HCC1569 NYLHPJNPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTF4LkizN|ch|ryP NUXZdlVOW0GQR1XS
SK-MES-1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HOUWlEPTB;MU[uPFQyQSEQvF2= NWnhZpNsW0GQR1XS
BB65-RCC MnfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPqTWM2OD1zNz6wOFc6KM7:TR?= M1\zWHNCVkeHUh?=
LOXIMVI NG\WfWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2e3cWlEPTB;MUeuNFcxPyEQvF2= MWPTRW5ITVJ?
SW1783 M4K5dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjQZ3pKSzVyPUG3MlEzQCEQvF2= MWLTRW5ITVJ?
NH-12 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HMWWlEPTB;MUeuN|MxOyEQvF2= NF25R3RUSU6JRWK=
UACC-257 NIni[m9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2i2OmlEPTB;MUeuOVUyOiEQvF2= M4KxSnNCVkeHUh?=
KOSC-2 NWnrflllT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH[2eohKSzVyPUG3MlY4PTdizszN NEDaTHBUSU6JRWK=
KG-1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;3ZWlEPTB;MUeuOlk{PyEQvF2= MXHTRW5ITVJ?
M059J MoTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jtNGlEPTB;MUeuO|A{KM7:TR?= NVG0XpBjW0GQR1XS
MHH-NB-11 M2nZ[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\ZcpV3UUN3ME2xO{46Pjd|IN88US=> MWPTRW5ITVJ?
EW-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3m3VGlEPTB;MUiuNVM5OiEQvF2= MX\TRW5ITVJ?
CAL-85-1 NWKz[FdYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\oZnJoUUN3ME2xPE4zOzV5IN88US=> MoPsV2FPT0WU
639-V M4L6VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTF6LkOzOVQh|ryP MoX6V2FPT0WU
C32 NV3JTXdwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFG2PI9KSzVyPUG4MlQ4OjdizszN MmHEV2FPT0WU
KM-H2 NVX5cWtUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXMcVFxUUN3ME2xPE42OjN{IN88US=> NGP3XnVUSU6JRWK=
A253 MkH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\QS5NKSzVyPUG4MlczQDZizszN NXLnWnBNW0GQR1XS
NCI-N87 NHKxVVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTF6LkmwNFgh|ryP NWr5UGF7W0GQR1XS
8-MG-BA NWXBeXVUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrKTWM2OD1zOT6wOlQ3KM7:TR?= MoD5V2FPT0WU
GI-ME-N NVPKRodtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV6xXYJ6UUN3ME2xPU4yPTR4IN88US=> NF;aO5dUSU6JRWK=
8305C MmTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jxZmlEPTB;MUmuNlI5PiEQvF2= MUXTRW5ITVJ?
TE-8 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknMTWM2OD1zOT6zNFI1KM7:TR?= NYjHeopjW0GQR1XS
KYSE-270 M1X5TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTJyLkCyNVch|ryP NEOweJdUSU6JRWK=
HL-60 M3rufmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XmPWlEPTB;MkCuNFk1OSEQvF2= M3zoOnNCVkeHUh?=
Mo-T NUO5WYVlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTJyLkG2OlUh|ryP NInxNFdUSU6JRWK=
NCI-H1355 MnTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETldYJKSzVyPUKwMlM{PzRizszN NETxfGVUSU6JRWK=
HT-1080 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTZbnVbUUN3ME2yNE42PDl5IN88US=> Ml25V2FPT0WU
MIA-PaCa-2 NYDiXm9YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojKTWM2OD1{MD62PFg{KM7:TR?= MWXTRW5ITVJ?
NCI-H441 M{nodmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\HW|F2UUN3ME2yNE44Ozd7IN88US=> MYXTRW5ITVJ?
LCLC-97TM1 NH7KUHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzoTWM2OD1{MD64NVM1KM7:TR?= NHjwblFUSU6JRWK=
HT-3 MmPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUCzPG91UUN3ME2yNU42PjNzIN88US=> MoTOV2FPT0WU
22RV1 M3e2[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLn[HRKSzVyPUKxMlU3QDVizszN MUTTRW5ITVJ?
LK-2 Mlr2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTJzLkW5OVMh|ryP M3[xe3NCVkeHUh?=
CW-2 NVjLVWp7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTJzLk[wOlkh|ryP Ml;zV2FPT0WU
KYSE-510 MlvuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rNXWlEPTB;MkGuOlA6PSEQvF2= MYfTRW5ITVJ?
CGTH-W-1 NFv5c41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2n1RmlEPTB;MkGuO|E3PiEQvF2= M{\PNnNCVkeHUh?=
NCI-H661 Mn74S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLiNXdTUUN3ME2yNk4xOzRizszN M1LCNnNCVkeHUh?=
KU-19-19 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfqSZlrUUN3ME2yNk4yPjl5IN88US=> NEC0SJpUSU6JRWK=
NCI-H2122 NV;PfldPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTJ{LkK0N|Ih|ryP MYrTRW5ITVJ?
NCI-H526 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rkPWlEPTB;MkKuN|g6PSEQvF2= MYLTRW5ITVJ?
NCI-H1650 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXyWVI6UUN3ME2yNk44PjRizszN NUTlXlI{W0GQR1XS
AM-38 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Moj3TWM2OD1{Mj64Olg6KM7:TR?= MUTTRW5ITVJ?
NCI-H2405 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnrcHpKSzVyPUKzMlI2OzNizszN NVTZTI9GW0GQR1XS
M14 NVHYbXhuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;1fGlEPTB;MkOuOFA5QCEQvF2= NHfMcm9USU6JRWK=
ES4 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWS3WZl{UUN3ME2yN{41OjN{IN88US=> NFSz[4ZUSU6JRWK=
DJM-1 NG[3eoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17NTGlEPTB;MkOuOVI{PCEQvF2= NEC4N29USU6JRWK=
S-117 MknsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PvdGlEPTB;MkOuO|Y2OSEQvF2= MV;TRW5ITVJ?
MZ2-MEL MkXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVGxTHl[UUN3ME2yN{44PzV7IN88US=> NV;RTlRqW0GQR1XS
SK-MEL-2 NU\PfINRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTJ|LkixN|Mh|ryP MV;TRW5ITVJ?
HCC1806 Mo\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4GzSGlEPTB;MkOuPFcxQSEQvF2= MlPNV2FPT0WU
NMC-G1 NWrGfZh1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPBSGNrUUN3ME2yOE4zOjJ4IN88US=> MnT1V2FPT0WU
DK-MG NYHkenBVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPnTWM2OD1{ND6yPVQh|ryP MYPTRW5ITVJ?
SK-N-FI NYezWolVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXpTWM2OD1{ND6zN|AzKM7:TR?= MoCwV2FPT0WU
KINGS-1 MlGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXmcGFKSzVyPUK0MlQ5PzRizszN NYXaRm45W0GQR1XS
HCC2998 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4Xuc2lEPTB;MkSuOFg5PSEQvF2= M1TtVHNCVkeHUh?=
ALL-PO MlvNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFOwZ4tKSzVyPUK0MlYyQSEQvF2= M3nxR3NCVkeHUh?=
MPP-89 NGnaTVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkP0TWM2OD1{NT6wOFU5KM7:TR?= MULTRW5ITVJ?
NCI-H2342 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnDXYljUUN3ME2yOU4yQTV|IN88US=> M1TKdXNCVkeHUh?=
TE-1 NYHjW4pLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrOcGxKSzVyPUK1MlM2PjNizszN NFTpOGpUSU6JRWK=
RH-18 M3n4emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LXZ2lEPTB;MkWuOVkyQCEQvF2= NEPkem5USU6JRWK=
HT-1376 NVTMNXpiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7aOY86UUN3ME2yOU43PDZ3IN88US=> MX\TRW5ITVJ?
U-2-OS MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfkUmNqUUN3ME2yOU43QDh6IN88US=> MV7TRW5ITVJ?
BT-549 NHTPc4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTJ3LkmwNVEh|ryP M2jxO3NCVkeHUh?=
NCI-H1755 NV3JV|JNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXNNppKSzVyPUK1Mlk6PDVizszN MmDwV2FPT0WU
EW-13 MnLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFu1VHdKSzVyPUK2MlAzPzRizszN MWnTRW5ITVJ?
NB13 NGm2To9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTJ4LkC5OFkh|ryP MojFV2FPT0WU
NUGC-3 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFP2[mFKSzVyPUK2MlIyODNizszN MUPTRW5ITVJ?
GMS-10 M4LK[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkGxTWM2OD1{Nj6yN|U{KM7:TR?= NXqxR|RpW0GQR1XS
CHP-134 MnzUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGXOdplKSzVyPUK2MlM5PjdizszN NXnYUG1SW0GQR1XS
SW962 NYHkfpVDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTJ4LkWwNlEh|ryP MoLtV2FPT0WU
SNU-449 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;ocIhKSzVyPUK3MlA5ODNizszN NUjNXpMyW0GQR1XS
HuP-T4 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnQbXZ[UUN3ME2yO{4xQDd7IN88US=> M3fMSXNCVkeHUh?=
SW948 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTQTWM2OD1{Nz6xN|Q1KM7:TR?= M2HYV3NCVkeHUh?=
NCI-H226 M1u0O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vhS2lEPTB;MkeuOFU4QCEQvF2= M4TLSHNCVkeHUh?=
SK-PN-DW NFrQN|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLKTWM2OD1{Nz62NFEzKM7:TR?= NYPq[mx7W0GQR1XS
GI-1 NFnMVJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILGbVdKSzVyPUK3MlczOSEQvF2= M2GxfHNCVkeHUh?=
CAL-12T NHfxOY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHLTWM2OD1{OD6xNVEzKM7:TR?= NHvFe29USU6JRWK=
YAPC MnnnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDofmVKSzVyPUK4MlI2PjRizszN M3Gwd3NCVkeHUh?=
SNU-C2B NXTIephxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLMTWM2OD1{OD6yPVY1KM7:TR?= MVPTRW5ITVJ?
RCC10RGB MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFywXWtKSzVyPUK4MlU1OTdizszN MofmV2FPT0WU
ES7 NH;WTXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPwUoc1UUN3ME2yPU4yPDZ3IN88US=> MYLTRW5ITVJ?
PANC-03-27 M4DPemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnrbFJKSzVyPUK5MlQ1PCEQvF2= NEDEcGVUSU6JRWK=
ES6 NVz5cXFbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVi2fWFnUUN3ME2yPU45OTV5IN88US=> MX3TRW5ITVJ?
HT-1197 M1HiZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGq4SFhKSzVyPUOwMlA2QThizszN MY\TRW5ITVJ?
ZR-75-30 NI\DWVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3qyOGlEPTB;M{CuNlM5OyEQvF2= M1HsTXNCVkeHUh?=
DB MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTNyLkS5OFIh|ryP NVu1W5hDW0GQR1XS
OCI-AML2 MlO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUn3OWJMUUN3ME2zNU4xPjlizszN MWLTRW5ITVJ?
NCI-H2170 NWrH[XY4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTNzLki1NVYh|ryP NHvzfnJUSU6JRWK=
IST-MES1 MlmyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjGTWM2OD1|Mj6yPFk4KM7:TR?= NY\hb2FDW0GQR1XS
769-P MofTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1[xfWlEPTB;M{KuN|Y1OSEQvF2= NHrXZldUSU6JRWK=
COR-L23 M13US2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\nUWlEPTB;M{KuPVA4OyEQvF2= M3jYWXNCVkeHUh?=
SW626 MnS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mkn2TWM2OD1|Mz6xO|c3KM7:TR?= NHzsOGdUSU6JRWK=
LU-139 Ml;5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUD4fpBSUUN3ME2zN{43PjB3IN88US=> M4T1S3NCVkeHUh?=
HT-144 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTN|Lki2N{DPxE1? MVfTRW5ITVJ?
CaR-1 NITVfYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HBU2lEPTB;M{OuPVgzOiEQvF2= NH64UXNUSU6JRWK=
OE33 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTN2LkK4OVUh|ryP M3fSenNCVkeHUh?=
COLO-800 M2naPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3r4V2lEPTB;M{SuN|Y1PyEQvF2= NWnJZlJEW0GQR1XS
NB14 NYfqTlRwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mni5TWM2OD1|ND60Olg1KM7:TR?= NVf0dI9tW0GQR1XS
KURAMOCHI M1fyUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTN4LkGxPVgh|ryP MV;TRW5ITVJ?
SW48 MnHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mor5TWM2OD1|Nj6yOFc1KM7:TR?= MoWwV2FPT0WU
Daoy NV7wVIlET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3K3bmlEPTB;M{[uOlU{QCEQvF2= M4\HTXNCVkeHUh?=
TGBC24TKB NETOcYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vDTmlEPTB;M{[uOlch|ryP NVXUWIlXW0GQR1XS
DU-4475 NXno[IVyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTvd|lKSzVyPUO2MlkxOzNizszN NIOzVnlUSU6JRWK=
SW1417 M{nEZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH35OVZKSzVyPUO4MlA2PTJizszN NX;qTWE1W0GQR1XS
EFO-21 NUKwWVM4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHzSpVqUUN3ME2zPE46OzR7IN88US=> MXXTRW5ITVJ?
MG-63 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHyOFBbUUN3ME2zPU4{PDJ2IN88US=> MULTRW5ITVJ?
LC-2-ad M4HvTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLHZoFtUUN3ME2zPU42PTF{IN88US=> MmH0V2FPT0WU
NOMO-1 M2C3eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTN7LkiyO|Qh|ryP NVHrVmw6W0GQR1XS
COLO-741 NFfOO4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTRyLkGzNFQh|ryP NXfjUnBlW0GQR1XS
BxPC-3 NHLrdGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIL1dnJKSzVyPUSwMlU3QDZizszN MX7TRW5ITVJ?
HSC-2 Mk[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXGySZI1UUN3ME20NE46OTF|IN88US=> Mnn0V2FPT0WU
UMC-11 MnfuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXMflhKSzVyPUSxMlI3OyEQvF2= MonUV2FPT0WU
HCC1937 M2izPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrSfWZOUUN3ME20Nk44QDR|IN88US=> MXLTRW5ITVJ?
Calu-6 NH\TdJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDON2hKSzVyPUSzMlI{QDJizszN M3vuOnNCVkeHUh?=
NCI-H1573 MkmyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TFbmlEPTB;NEOuN|Q4PyEQvF2= MnTwV2FPT0WU
SK-N-AS Mlm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\TbJNzUUN3ME20N{43ODF7IN88US=> M4LhSXNCVkeHUh?=
PSN1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTR3LkK1OFgh|ryP MlfrV2FPT0WU
TE-11 M3LKTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEn0[4lKSzVyPUS1MlQ5PDJizszN NVLqToZOW0GQR1XS
NCI-H1155 MnnoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1nMUWlEPTB;NEWuPFk3PyEQvF2= NVzqN5h3W0GQR1XS
KM12 NYDB[nh6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljqTWM2OD12NT65NFc3KM7:TR?= Ml2zV2FPT0WU
RO82-W-1 NF6xZXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfz[HptUUN3ME20Ok46QDJ{IN88US=> MnOyV2FPT0WU
SW1573 NVvCZpJQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTR5LkO3N|Yh|ryP NFnPcXRUSU6JRWK=
CAKI-1 NUXjSYJ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LZZWlEPTB;NEiuNlg1PSEQvF2= MYPTRW5ITVJ?
U-118-MG M4GyRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIKxUWZKSzVyPUS4MlM4ODJizszN Mn7OV2FPT0WU
KYSE-520 MmLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1HsOWlEPTB;NEiuOFAyPiEQvF2= MYnTRW5ITVJ?
HT55 NFPZSmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLQPXZKSzVyPUS5MlE1PzRizszN M1fUdHNCVkeHUh?=
ChaGo-K-1 MlnYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETMU2VKSzVyPUS5MlQ4QTNizszN MY\TRW5ITVJ?
IA-LM M4n0T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTre3Q1UUN3ME21OE43OzJ{IN88US=> MWnTRW5ITVJ?
UACC-62 NXPQZYszT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrKVIpKSzVyPUW1MlExPDZizszN MYfTRW5ITVJ?
MKN7 Mkn6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInYeohKSzVyPUW2MlAzQDVizszN NEjTSZpUSU6JRWK=
HPAF-II MlXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInDR5dKSzVyPUW2MlQxPzNizszN M{jvWXNCVkeHUh?=
NTERA-S-cl-D1 NVq0RnQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;UTWM2OD13Nz63O|gh|ryP MljtV2FPT0WU
FTC-133 M2q2[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TXWGlEPTB;NUiuNFk3QSEQvF2= MYDTRW5ITVJ?
MHH-ES-1 M1PjOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M160XWlEPTB;NUiuOFgyPCEQvF2= MnHnV2FPT0WU
JVM-2 NUHOdIVvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTV6Lkm1NFYh|ryP NXXaVmhqW0GQR1XS
TCCSUP MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTV7LkWyO|kh|ryP M3H2R3NCVkeHUh?=
COLO-824 NGXJS2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfIcmpVUUN3ME22NE4xPzF7IN88US=> MkjNV2FPT0WU
647-V NILhVZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTZyLkGzOFch|ryP M2XrVXNCVkeHUh?=
HD-MY-Z NU\WR2N3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jvZWlEPTB;NkCuOVI6PCEQvF2= MYXTRW5ITVJ?
LS-411N NE\Pc5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfUTWM2OD14MT6zPVA{KM7:TR?= MXjTRW5ITVJ?
NCI-H596 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPXPWZDUUN3ME22Nk44PDl4IN88US=> NWnuc5FDW0GQR1XS
C-33-A MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHlTWM2OD14ND6wPVU4KM7:TR?= NEG5doNUSU6JRWK=
BHY M3PLdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjWeWd7UUN3ME22OE4yOjR3IN88US=> MXHTRW5ITVJ?
KGN NE\Se2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTZ2LkW1NVQh|ryP MlHFV2FPT0WU
NCI-H1092 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmG4TWM2OD14NT6wNFk2KM7:TR?= MYHTRW5ITVJ?
MZ1-PC NGPwT5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTZ3LkW2OFkh|ryP NWToZoM{W0GQR1XS
LB831-BLC MlLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFuwSnlKSzVyPU[1Mlg1QDFizszN NYr4cW9{W0GQR1XS
SW620 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTZ4LkKwN|kh|ryP NWLPO41mW0GQR1XS
HuO-3N1 M1\UPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\BcGlEPTB;NkiuN|I{QCEQvF2= MkC1V2FPT0WU
SK-HEP-1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEezRXlKSzVyPU[5Mlk1QDZizszN NE\adHJUSU6JRWK=
LCLC-103H NImyPHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;UTWM2OD15MD62O|A2KM7:TR?= NFrobWNUSU6JRWK=
KYSE-70 NWfwR3ZrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{faUGlEPTB;N{CuO|g{PSEQvF2= NVXTS5hPW0GQR1XS
Mewo MnfYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PafGlEPTB;N{GuOVA2KM7:TR?= NU\FWVFXW0GQR1XS
COLO-668 MlPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTdzLki0OVEh|ryP NILrSJhUSU6JRWK=
NCI-H522 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkH5TWM2OD15Mj6zOFE{KM7:TR?= MlnEV2FPT0WU
NCI-H1437 NVfxW2ZET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33GU2lEPTB;N{SuOFA1QCEQvF2= MV3TRW5ITVJ?
U-266 M2K1WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnzPIlKSzVyPUe1MlQ2OTZizszN M{fJeXNCVkeHUh?=
MC116 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHhSFhKSzVyPUe1MlU4ODhizszN M3WxcHNCVkeHUh?=
PANC-10-05 NGHrNYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHoTmZkUUN3ME23O{41OjR|IN88US=> MYPTRW5ITVJ?
KYSE-180 NYTJNpZXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPaTWM2OD15Nz61OFU1KM7:TR?= MnHrV2FPT0WU
JAR M1zpZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTd7LkC1OFYh|ryP NUnKWY1tW0GQR1XS
CAL-62 NXHSdVZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjIRVFPUUN3ME24NE4xQTVizszN MnT3V2FPT0WU
A3-KAW MmjWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DtVmlEPTB;OECuNlE2PCEQvF2= MYjTRW5ITVJ?
PANC-08-13 NUDHcJdNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRThzLkG3Olgh|ryP MmXtV2FPT0WU
HSC-3 NX3OUGh1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zkO2lEPTB;OEOuN|A4OSEQvF2= MV;TRW5ITVJ?
HTC-C3 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{K2UmlEPTB;OEOuOFcxOiEQvF2= NUnzNm8{W0GQR1XS
KY821 NGXt[IVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTh2LkC4PVIh|ryP MorrV2FPT0WU
DoTc2-4510 MoLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTh2LkKxPFUh|ryP NV;ZfpdQW0GQR1XS
NCI-H1581 NHTySoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrIW|JKSzVyPUi1MlQ3PDFizszN NWXw[|RlW0GQR1XS
KARPAS-299 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfjXJBKSzVyPUi2MlE6PzdizszN MnXtV2FPT0WU
IST-MEL1 NVP2ZoN6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1v2NGlEPTB;OE[uPFg4OiEQvF2= NG\KTo5USU6JRWK=
KP-N-YS NFzFVIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXVTWM2OD16OT65NFI5KM7:TR?= NH\DOG5USU6JRWK=
KYSE-410 M17qcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjSVIdDUUN3ME25NU41ODR{IN88US=> NV76[GI2W0GQR1XS
TE-10 Ml24S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjwS2VWUUN3ME25NU42PjFzIN88US=> NIS3e3FUSU6JRWK=
SK-MEL-1 NXvZdlczT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDMflFLUUN3ME25Nk46OTB4IN88US=> MlTNV2FPT0WU
COLO-792 NWLm[YV5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{i2WGlEPTB;OUWuNlU3PCEQvF2= NG\yfHBUSU6JRWK=
SCH MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{P0RmlEPTB;OU[uN|g4PyEQvF2= NWP3W5pyW0GQR1XS
NCI-H1792 M1TFT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrYUFVKSzVyPUm2Mlg6QTJizszN NW\DTmpqW0GQR1XS
NCI-H2029 M1[weGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHETWM2OD17Nj65OVY3KM7:TR?= MVXTRW5ITVJ?
SW684 MkH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTLbYRmUUN3ME25PE43PjV2IN88US=> M{W1ZnNCVkeHUh?=
NCI-H209 NXrqd4dbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLhZ25oUUN3ME2xNFAvOTJzIN88US=> NXWwXWx5W0GQR1XS
HLE MmG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkW2TWM2OD1zMEWuNlgzKM7:TR?= NVLVRncyW0GQR1XS
GOTO Mk[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoqzTWM2OD1zMEeuO|c4KM7:TR?= NG\2O4JUSU6JRWK=
NCI-H1793 M4\WXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF23RXpKSzVyPUGwPU4zQCEQvF2= M{S1RnNCVkeHUh?=
D-392MG MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3IZY1vUUN3ME2xNVcvOzl6IN88US=> Moi0V2FPT0WU
SW1990 MoPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmX3TWM2OD1zMkCuPVUyKM7:TR?= MnjFV2FPT0WU
ML-2 NITUcoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nCdWlEPTB;MUKxMlY4PiEQvF2= M{XSUnNCVkeHUh?=
NCI-H2452 Ml;zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTF{Mj6yNUDPxE1? NX;rWo54W0GQR1XS
SK-MEL-30 NFHDfJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLkTWM2OD1zMkOuNlQ1KM7:TR?= MWLTRW5ITVJ?
SN12C MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXNW4w5UUN3ME2xNlQvOTd4IN88US=> M2\URnNCVkeHUh?=
NCI-H1770 NYHxOIF[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonETWM2OD1zMkWuOVE1KM7:TR?= MVHTRW5ITVJ?
SF268 MnnxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnkTWM2OD1zMk[uNVU5KM7:TR?= MUTTRW5ITVJ?
BALL-1 NWCz[Xp2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4m3Z2lEPTB;MUK2MlI{KM7:TR?= NHzPbZFUSU6JRWK=
COLO-679 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWH5T4lEUUN3ME2xNlYvPzV|IN88US=> NIfTTHRUSU6JRWK=
A2780 NX3nUmQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGn2VYFKSzVyPUGyPE46QDhizszN MYfTRW5ITVJ?
NCI-H1651 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHyb2VDUUN3ME2xN|EvOjR|IN88US=> MlHGV2FPT0WU
NCI-H2087 MoHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTF|MT60PFMh|ryP MYLTRW5ITVJ?
U-87-MG NXXBfWx3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTF|Mz62NFQh|ryP MWrTRW5ITVJ?
LB2518-MEL NF\xfnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PZS2lEPTB;MUO1Mlk6OyEQvF2= M{fld3NCVkeHUh?=
HCT-116 Mo\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfWO4hKSzVyPUGzO{4zOTdizszN MnvXV2FPT0WU
Ca9-22 NGfQNYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTF|OT64N|Mh|ryP MXjTRW5ITVJ?
COR-L88 MnzlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojOTWM2OD1zNEKuNVQh|ryP M3\YRnNCVkeHUh?=
CP50-MEL-B MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XTS2lEPTB;MUS0MlUxOSEQvF2= NX[1[nFxW0GQR1XS
OVCAR-8 NGLYSnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvYTWM2OD1zNEWuOlM3KM7:TR?= MVnTRW5ITVJ?
SK-MEL-3 M{DBZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXS2NFZlUUN3ME2xOFcvQDd6IN88US=> NIG1eHBUSU6JRWK=
GT3TKB M1nWS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHBTWM2OD1zNEmuPVI5KM7:TR?= NVrpOlBZW0GQR1XS
KYSE-450 MlvWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fRUGlEPTB;MUWxMlU{QSEQvF2= NGrrepdUSU6JRWK=
CAPAN-1 NHH1R2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1mwR2lEPTB;MUWzMlA3PCEQvF2= NVLTTJp5W0GQR1XS
BEN MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzaNZlKSzVyPUG1N{46OjhizszN M370SHNCVkeHUh?=
NCI-H1304 MmT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfQWHVKSzVyPUG1OE43QTRizszN NXP5clhJW0GQR1XS
KU812 MmDyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIG5XGlKSzVyPUG1PE43PzRizszN MX7TRW5ITVJ?
Capan-2 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlu0TWM2OD1zNkCuOVU{KM7:TR?= MWTTRW5ITVJ?
A673 Ml7iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjXTWM2OD1zNkGuO|A2KM7:TR?= MXvTRW5ITVJ?
SAS NIDxd|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTF4Mj62O|gh|ryP MmrXV2FPT0WU
NY NIrvVWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HaWWlEPTB;MU[1MlMyPCEQvF2= M1PscHNCVkeHUh?=
HCE-4 NVjVSZdxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HlcmlEPTB;MU[2Mlg1PSEQvF2= NHXidoFUSU6JRWK=
MDA-MB-231 M4TTOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHCbXBKSzVyPUG3O{42ODNizszN NFvze2tUSU6JRWK=
no-10 MlXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHGzWHVKSzVyPUG3PE4yOzRizszN NFyxeINUSU6JRWK=
MZ7-mel MlHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPOZ2tMUUN3ME2xO|gvPDZ5IN88US=> NHfCZVlUSU6JRWK=
NCI-H82 NXjVTlNLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4i2bGlEPTB;MUiwMlE3PSEQvF2= M{\2e3NCVkeHUh?=
CAL-72 M2TkPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3r3[2lEPTB;MUi1MlA2PCEQvF2= MmHlV2FPT0WU
NCI-SNU-5 NHTDZplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;KN|VyUUN3ME2xPFYvQDRizszN M{fP[XNCVkeHUh?=
OVCAR-4 NGPNNGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzPeWo5UUN3ME2xPFgvOzN|IN88US=> M33Z[nNCVkeHUh?=
SCC-9 MoDoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTF7MTFOwG0> MVzTRW5ITVJ?
KYSE-150 M4fHXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYGzRWM5UUN3ME2xPVEvQDh6IN88US=> NEXXPXdUSU6JRWK=
HT-29 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXy3TYlVUUN3ME2yNFEvOjF{IN88US=> MkTnV2FPT0WU
COLO-678 NVf2WpR2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHLXYVqUUN3ME2yNFEvPDVizszN NF\4em1USU6JRWK=
NCI-H650 MknDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDJfmZGUUN3ME2yNFIvOTB|IN88US=> NGPOU4pUSU6JRWK=
HuCCT1 NU\4ZVlHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DkSmlEPTB;MkC0MlIxQCEQvF2= NXrDdXJPW0GQR1XS
SW1116 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXO5bJl3UUN3ME2yNFcvODd5IN88US=> M1rHNXNCVkeHUh?=
DBTRG-05MG NWnNNYx6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX[0ZlU{UUN3ME2yNFcvQTB7IN88US=> NVHRTZhDW0GQR1XS
SW982 MmrOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvVTIhKSzVyPUKwO{46PDhizszN NIXzfpVUSU6JRWK=
RCM-1 MoDaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYrCZXJlUUN3ME2yNVQvPzZ{IN88US=> MlHpV2FPT0WU
COLO-320-HSR NEToPYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;ET2lEPTB;MkG2MlEzPSEQvF2= MXHTRW5ITVJ?
KNS-42 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTJzNj61O|Qh|ryP M4SyWHNCVkeHUh?=
C2BBe1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjQVW9FUUN3ME2yN|EvQTB3IN88US=> NF;MXJNUSU6JRWK=
CCRF-CEM MlPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHUR3JKSzVyPUK0N{44QTVizszN NFT2[ldUSU6JRWK=
SH-4 NHTZb2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTJ2Nj6wPUDPxE1? Mk[wV2FPT0WU
LS-1034 NHLwcXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVz6PJEyUUN3ME2yOFYvOjZ4IN88US=> NGPtUWdUSU6JRWK=
NCI-H2347 M1:0Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV71VYhIUUN3ME2yOFcvPzF|IN88US=> M3y2V3NCVkeHUh?=
RPMI-8866 MkTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfTNoZKSzVyPUK0PU4zPyEQvF2= M3;a[nNCVkeHUh?=
GAK NFGzcJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVTPXIcyUUN3ME2yOVMvODB{IN88US=> M1LlbHNCVkeHUh?=
NB6 NWnEeYRTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLXbFJiUUN3ME2yO|AvOSEQvF2= NITnbVJUSU6JRWK=
COLO-680N M2H1PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zjNWlEPTB;MkeyMlUzPyEQvF2= NEL1bWNUSU6JRWK=
RERF-LC-MS NEm0bWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmn0TWM2OD1{N{[uNFA4KM7:TR?= Mo\QV2FPT0WU
TGBC11TKB NGnseJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTJ5OD6xO|gh|ryP NF\SVZRUSU6JRWK=
C8166 NWXF[IJRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M121b2lEPTB;Mke4MlUxPiEQvF2= MXjTRW5ITVJ?
HDLM-2 M2DLdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHXSnE{UUN3ME2yPVQvPDB7IN88US=> M4DW[XNCVkeHUh?=
IGR-1 M3nSOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4i0S2lEPTB;Mkm1MlY2QSEQvF2= M3zwUnNCVkeHUh?=
FADU NWTFNHZzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHGyPHBKSzVyPUK5O{42OSEQvF2= NV7JXGhQW0GQR1XS
L-428 NV2zXmVHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDQTWM2OD1{OUeuOlE3KM7:TR?= NUDKOnZlW0GQR1XS
LU-65 NX7OPFM5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;ud21ZUUN3ME2zNFQvOzJizszN NGPQNppUSU6JRWK=
HEL NVf1XHNKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzsXXZLUUN3ME2zNFkvQTh|IN88US=> MWrTRW5ITVJ?
NCI-H810 NUfEPGZ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTNzMD61O{DPxE1? M1\xbHNCVkeHUh?=
C3A M2e1eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTNzMT64NFIh|ryP M1ftWXNCVkeHUh?=
NCI-H630 M4WyXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPGV5lKSzVyPUOzNk4zQTRizszN M3XxSHNCVkeHUh?=
KP-N-YN MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PoVGlEPTB;M{SxMlEzOyEQvF2= Mlj3V2FPT0WU
MOLT-13 M1Lzcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmq5TWM2OD1|NEKuN|I3KM7:TR?= M1HhO3NCVkeHUh?=
NCI-H1993 NITMNIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLsTWM2OD1|NEKuN|Y2KM7:TR?= M2PLWXNCVkeHUh?=
BE-13 NIL3cJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnsTWM2OD1|NESuNVY4KM7:TR?= NFnEdFVUSU6JRWK=
IST-SL1 M2XKV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTN2Nz60NFEh|ryP NYjCb3hNW0GQR1XS
TE-9 MnLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\zTWM2OD1|NkOuOVg6KM7:TR?= M3qzU3NCVkeHUh?=
LU-135 NGK4UWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnKZmI5UUN3ME2zOlcvODN3IN88US=> MY\TRW5ITVJ?
T84 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPi[YVKSzVyPUO3OE44OTJizszN MV\TRW5ITVJ?
K-562 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITBOGJKSzVyPUO4N{4{PiEQvF2= MlTVV2FPT0WU
SBC-5 NIWye3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXj2eZl7UUN3ME2zPFYvQTh3IN88US=> M2jtcnNCVkeHUh?=
NB17 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfJToVoUUN3ME2zPVIvPTl4IN88US=> NHLxSZRUSU6JRWK=
NCI-H2052 M1[3UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PabWlEPTB;M{m4MlQ4OiEQvF2= MWPTRW5ITVJ?
HCC38 MkPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTiSWRKSzVyPUSwNU42QTNizszN NXrPVlJNW0GQR1XS
NCI-H69 NFjXdI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\hTWM2OD12NEGuNFg{KM7:TR?= MYPTRW5ITVJ?

... Click to View More Cell Line Experimental Data
In vivo MK-2206 shows 60% TGI and inhibits more than 70 % of phospho-Akt1/2 (T308 and S473) in A2780 ovarian cancer xenografts at a dose of 240 mg/kg. [1] MK-2206 exhibits significant antitumor activity in NCI-H292 xenograft in combination with erlotinib or lapatinib. [2]

Protocol

Kinase Assay:[4]
+ Expand

Akt kinases assay:

Akt kinases are assayed by a GSK-derived biotinylated peptide substrate. The extent of peptide phosphorylation is determined by Homogeneous Time Resolved Fluorescence (HTRF) using a lanthanide chelate (Lance)-coupled monoclonal antibody specific for the phosphopeptide in combination with a streptavidin-linked allophycocyanin (SA-APC) fluorophore which will bind to the biotin moiety on the peptide. When the Lance and APC are in proximity, a non-radiative energy transfer takes place from the Lance to the APC, followed by emission of light from APC at 655 nm. Working Solution: 100X protease inhibitor cocktail (PIC): 1mg/mL benzamidine, 0.5 mg/mL pepstatin, 0.5 mg/mL leupeptin, 0.5 mg/mL aprotinin; 10X assay buffer: 500 mM HEPES, pH7.5, 1% PEG, 16.6 mM EDTA, 1 mM EGTA, 1% BSA, 20 mM 9-glycerol phosphate; Quench buffer 50 mM HEPES pH 7.3, 16.6 mM EDTA, 0.1% BSA, 0.1% Triton X-100, 0.17 nM labeled monoclonal antibody, 0.0067 mg/mL SA-APC; ATP/MgCl2 working solution: 1X Assay buffer, 1 mM DTT, 1X PIC, 5% glycerol, active Akt; Peptide working solution: 1X Assay buffer, 1 mM DTT, 1X PIC, 5% glycerol, 2 TM GSK biotinylated peptide. The reaction is assembled by adding 16 µL of ATP/MgCl2 working solution to the appropriate wells. MK-2206 or vehicle (1.0 µL) is added followed by 10 µL of peptide working solution. The reaction is started by adding 13 μL of the enzyme working solution and mixing. The reaction is allowed to proceed for 50 min and then stopped by the addition of 60 µL HTRF quench buffer. The stopped reactions are incubated at room temperature for at least 30 min and then read in the instrument.
Cell Research:[2]
+ Expand
  • Cell lines: A431, HCC827, NCI-H292, NCI-H358, NCI-H23, NCI-H1299, Calu-6 and NCI-H460 cells
  • Concentrations: 0, 0.3, 1 and 3 μM
  • Incubation Time: 72 or 96 hours
  • Method: MK-2206 is dissolved in DMSO as a stock solution and diluted by culture media before use. Cells are seeded at a density of 2-3 × 103 in 96-well plates and incubated for 24 hours. Then MK-2206 (0, 0.3, 1 and 3 μM) is added to the cells. Cell proliferation is determined after 72 or 96 hours.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: SK-OV-3, NCI-H292, HCC70, PC-3, and NCI-H460 models in male CD1-nude mice
  • Formulation: Formulated in 30% Captisol
  • Dosages: 120 mg/kg
  • Administration: Orally administered
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 14 mg/mL (29.14 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents individually and in order:
15% Captisol		 17 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 480.39
Formula

C25H21N5O.2HCl
CAS No. 1032350-13-2
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01306045 Recruiting Carcinoma, Non-Small-Cell Lung|Carcinoma, Small Cell Lung|Carcinoma, Thymic National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) January 21, 2011 Phase 2
NCT01802320 Active, not recruiting Colon Mucinous Adenocarcinoma|Colon Signet Ring Cell Adenocarcinoma|Rectal Mucinous Adenocarcinoma|Rectal Signet Ring Cell Adenocarcinoma|Recurrent Colon Carcinoma|Recurrent Rectal Carcinoma|Stage IIIA Colon Cancer|Stage IIIA Rectal Cancer|Stage IIIB Colon Cancer|Stage IIIB Rectal Cancer|Stage IIIC Colon Cancer|Stage IIIC Rectal Cancer|Stage IVA Colon Cancer|Stage IVA Rectal Cancer|Stage IVB Colon Cancer|Stage IVB Rectal Cancer National Cancer Institute (NCI) March 2013 Phase 2
NCT01783171 Active, not recruiting Pancreatic Adenocarcinoma|Recurrent Pancreatic Carcinoma|Stage III Pancreatic Cancer|Stage IV Pancreatic Cancer|Unresectable Pancreatic Carcinoma National Cancer Institute (NCI) January 2013 Phase 1
NCT01776008 Active, not recruiting Estrogen Receptor Positive|HER2/Neu Negative|Recurrent Breast Carcinoma|Stage IIA Breast Cancer|Stage IIB Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer National Cancer Institute (NCI) January 2013 Phase 2
NCT01859182 Withdrawn Adenocarcinoma of the Gallbladder|Adenocarcinoma With Squamous Metaplasia of the Gallbladder|Adult Primary Cholangiocellular Carcinoma|Advanced Adult Primary Liver Cancer|Cholangiocarcinoma of the Extrahepatic Bile Duct|Localized Unresectable Adult Primary Liver Cancer|Metastatic Extrahepatic Bile Duct Cancer|Recurrent Adult Primary Liver Cancer|Recurrent Extrahepatic Bile Duct Cancer|Stage II Gallbladder Cancer|Stage IIIA Gallbladder Cancer|Stage IIIB Gallbladder Cancer|Stage IVA Gallbladder Cancer|Stage IVB Gallbladder Cancer|Unresectable Extrahepatic Bile Duct Cancer National Cancer Institute (NCI) January 2013 Phase 2
NCT01705340 Terminated Adenocarcinoma of the Gastroesophageal Junction|HER2-positive Breast Cancer|Male Breast Cancer|Recurrent Breast Cancer|Recurrent Esophageal Cancer|Recurrent Gastric Cancer|Stage IIIC Breast Cancer|Stage IIIC Esophageal Cancer|Stage IIIC Gastric Cancer|Stage IV Breast Cancer|Stage IV Esophageal Cancer|Stage IV Gastric Cancer National Cancer Institute (NCI) September 2012 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What is your recommendation for preparing the solution and how would you deliver it to the mice (i.p. or gavage)?

  • Answer:

    You can resuspend MK-2206 in 15% Captisol at up to 17mg/ml. It's a suspension and is for oral gavage use only.

  • Question 2:

    I would want to know if MK-2206 could cross the blood brain barrier?

  • Answer:

    MK-2206 can cross BBB based on the following reference: https://clinicaltrials.gov/ct2/show/NCT01249105.

selleck catalog

Akt Signaling Pathway Map

Akt Inhibitors with Unique Features

  • Selective Akt Inhibitor

    CCT128930 AKT2-selective, IC50=6 nM.

  • Most Potent Akt Inhibitor

    AZD5363 Akt1, IC50=3 nM; Akt2, IC50=8 nM; Akt3, IC50=8 nM.

  • Akt Inhibitor in Clinical Trial

    Perifosine (KRX-0401) Phase III fro relapsed and refractory multiple myeloma.

  • Newest Akt Inhibitor

    AZD5363 Potent inhibitor of all isoforms of Akt (Akt1/Akt2/Akt3) with IC50 of 3 nM/8 nM/8 nM, similar to P70S6K/PKA and lower activity towards ROCK1/2.

Related Akt Products

  • Afuresertib (GSK2110183) New

    Afuresertib (GSK2110183) is a potent, orally bioavailable Akt inhibitor with Ki of 0.08 nM, 2 nM, and 2.6 nM for Akt1, Akt2, and Akt3, respectively. Phase 2.

  • AT13148 New

    AT13148 is an oral, ATP-competitive, multi-AGC kinase inhibitor with IC50 of 38 nM/402 nM/50 nM, 8 nM, 3 nM, and 6 nM/4 nM for Akt1/2/3, p70S6K, PKA, and ROCKI/II, respectively. Phase 1.

  • SC79 New

    SC79 is a brain-penetrable Akt phosphorylation activator and an inhibitor of Akt-PH domain translocation.

  • AZD5363

    AZD5363 potently inhibits all isoforms of Akt(Akt1/Akt2/Akt3) with IC50 of 3 nM/8 nM/8 nM in cell-free assays, similar to P70S6K/PKA and lower activity towards ROCK1/2. Phase 2.

    Features:Moderate preclinical tolerability, and PD characteristics of an AKT inhibitor. Distinct profile from other AKT inhibitors in clinical development.

  • Ipatasertib (GDC-0068)

    Ipatasertib (GDC-0068) is a highly selective pan-Akt inhibitor targeting Akt1/2/3 with IC50 of 5 nM/18 nM/8 nM in cell-free assays, 620-fold selectivity over PKA. Phase 2.

  • GSK690693

    GSK690693 is a pan-Akt inhibitor targeting Akt1/2/3 with IC50 of 2 nM/13 nM/9 nM in cell-free assays, also sensitive to the AGC kinase family: PKA, PrkX and PKC isozymes. Phase 1.

  • Perifosine (KRX-0401)

    Perifosine (KRX-0401) is a novel Akt inhibitor with IC50 of 4.7 μM in MM.1S cells, targets pleckstrin homology domain of Akt. Phase 3.

  • A-674563

    A-674563 is an Akt1 inhibitor with Ki of 11 nM in cell-free assays, modest potent to PKA and >30-fold selective for Akt1 over PKC.

    Features:Orally bioavailable compound (achieved by replacing indole of A-443654 with phenyl moiety) and somewhat less selective for Akt over PKA than A-443654.

  • Triciribine

    Triciribine is a DNA synthesis inhibitor, also inhibits Akt in PC3 cell line and HIV-1 in CEM-SS, H9, H9IIIB, U1 cells with IC50 of 130 nM and 20 nM, respectively; does not inhibit PI3K/PDK1; 5000-fold less active in cells lacking adenosine kinase. Phase 1/2.

  • Honokiol

    Honokiol is the active principle of magnolia extract that inhibits Akt-phosphorylation and promotes ERK1/2 phosphorylation. Phase 3.

Tags: buy MK-2206 2HCl | MK-2206 2HCl supplier | purchase MK-2206 2HCl | MK-2206 2HCl cost | MK-2206 2HCl manufacturer | order MK-2206 2HCl | MK-2206 2HCl distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID